InvestigationalReviewed July 25, 2026
Peptide analog
Retatrutide
Also called Reta
An experimental weight-loss drug that is also being studied for type 2 diabetes. It is not approved.
Controlled human studyRegistered trial — no results
FDA approved for defined indicationsReviewed July 25, 2026
Peptide analog
Tirzepatide
Also called Tirz
A drug used for weight loss or type 2 diabetes, depending on the product. Brands include Zepbound and Mounjaro.
Controlled human studyOther human evidence
FDA approved for defined product-specific indicationsReviewed July 25, 2026
Peptide analog
Semaglutide
Also called Sema
A drug used for weight loss or type 2 diabetes, depending on the product. It comes in injection and tablet forms.
Controlled human studyOther human evidence
InvestigationalReviewed July 25, 2026
Defined peptide
MOTS-c
An experimental peptide studied for how the body uses energy. People often look into it for metabolism and exercise.
Other human evidenceAnimal study
FDA approved for a defined indicationReviewed July 25, 2026
Peptide analog
Tesamorelin
Also called Tesa
A drug used to reduce excess deep belly fat in adults with HIV-related changes in fat distribution. It is not a general weight-loss drug.
Controlled human studyOther human evidence
Investigational — Phase 3Reviewed July 25, 2026
Peptide analog
Cagrilintide
Also called Cagri
An experimental weight-loss drug designed to help people feel full after eating. It is not approved on its own.
Controlled human studyRegistered trial — no results
Investigational — U.S. application under reviewReviewed July 25, 2026
Peptide blend
CagriSema
An experimental weight-loss drug combining cagrilintide and semaglutide in one studied product.
Controlled human studyOther human evidence
FDA approved for defined product-specific indicationsReviewed July 25, 2026
Peptide analog
Liraglutide
Also called Lira
A drug used for diabetes or weight management, depending on the product. Brands include Victoza and Saxenda.
Controlled human studyOther human evidence
Not FDA approvedReviewed July 25, 2026
Small molecule
5-Amino-1MQ
Also called 5A-1MQ
An experimental compound often discussed for fat loss. It is a small molecule, not a peptide.
Animal studyLaboratory study
Not FDA approved — obesity program terminatedReviewed July 30, 2026
Defined peptide
AOD-9604
Also called AOD
An unapproved peptide often discussed for fat loss. It is based on a small part of growth hormone.
Controlled human studyOther human evidence
Investigational — Phase 2 obesity results; Phase 3 registeredReviewed July 31, 2026
Peptide analog
CT-388
An experimental weight-loss drug, also called enicepatide. It is being tested for obesity and blood-sugar control.
Controlled human studyOther human evidence
Investigational — early MASH-focused human developmentReviewed July 31, 2026
Peptide analog
Efocipegtrutide
An experimental drug being studied for fatty-liver disease and weight-related health problems.
Other human evidenceRegistered trial — no results
Investigational — Phase 3Reviewed July 30, 2026
Peptide analog
Eloralintide
Also called Elora
An experimental weight-loss drug designed to affect fullness and appetite.
Controlled human studyRegistered trial — no results
No single FDA-approved product, standardized formula, or recognized research identity exists under the name Fat Blaster Blend.Reviewed July 31, 2026
Unstandardized mixture
Fat Blaster Blend
A marketing name for mixtures sold around fat-loss or energy claims. It does not identify one standard formula.
No direct evidence locatedMechanistic rationale
Preclinical; no FDA-approved Humanin product.Reviewed July 31, 2026
Defined peptide
Humanin
An experimental peptide studied for cell protection and aging-related biology. The body also makes it naturally.
Other human evidenceLaboratory study
Investigational; no FDA-approved ibutamoren product.Reviewed July 31, 2026
Small molecule
Ibutamoren
Also called MK-677
An experimental pill that raises growth hormone and related growth signals. It is not a peptide.
Controlled human studyNo direct evidence located
FDA-approved levocarnitine products exist for defined primary or secondary carnitine-deficiency indications; this does not approve general weight-loss use.Reviewed July 31, 2026
Amino-acid derivative
Levocarnitine
Also called L-Carnitine
A substance the body uses to turn fat into energy. Approved levocarnitine products treat specific deficiencies.
Controlled human studyOther human evidence
No single FDA-approved Lipo-C formula or standardized research identity.Reviewed July 31, 2026
Unstandardized mixture
Lipo-C
A name used for varying vitamin and nutrient mixtures, often marketed for weight loss or energy.
No direct evidence locatedMechanistic rationale
Investigational — Phase 3 antibody–peptide conjugateReviewed July 31, 2026
Antibody–peptide conjugate
MariTide
An experimental weight-loss drug designed to work with less frequent injections.
Controlled human studyLaboratory study
Approved in China — not FDA approvedReviewed July 31, 2026
Peptide analog
Mazdutide
A weight-loss and diabetes drug approved in China. It is not FDA approved in the United States.
Controlled human studyOther human evidence
Investigational — controlled MASH and obesity evidenceReviewed July 31, 2026
Peptide analog
Pemvidutide
An experimental drug being studied for weight loss and fatty-liver disease.
Controlled human studyAnimal study
Investigational — Phase 2 obesity evidenceReviewed July 31, 2026
Peptide analog
Petrelintide
An experimental weight-loss drug designed to help people feel full after eating.
Controlled human studyOther human evidence
Investigational fixed research combination; a direct combination trial is registered, with no posted outcome results at the cutoff.Reviewed July 31, 2026
Peptide blend
Petrelintide + CT-388
An experimental weight-loss combination of petrelintide and CT-388, also called enicepatide.
Registered trial — no resultsNo direct evidence located
Preclinical; no FDA-approved product and no administered-human outcome study located.Reviewed July 31, 2026
Small molecule
SLU-PP-332
An experimental compound discussed for endurance and fat metabolism. It is a small molecule, not a peptide.
Animal studyNo direct evidence located
Investigational — published Phase 3 obesity evidenceReviewed July 31, 2026
Peptide analog
Survodutide
An experimental drug being studied for weight loss and a form of fatty-liver disease called MASH.
Controlled human studyRegistered trial — no results
Investigational; no FDA-approved tesofensine product.Reviewed July 31, 2026
Small molecule
Tesofensine
An experimental weight-loss pill that changes brain signals involved in appetite.
Controlled human studyNo direct evidence located
Investigational; active Phase 2 and Phase 3 programs, no FDA approval.Reviewed July 31, 2026
Peptide analog
UBT251
An experimental drug being studied for weight loss, diabetes, and fatty-liver disease.
Registered trial — no resultsNo direct evidence located
Investigational — Phase 3 injection and oral developmentReviewed July 31, 2026
Peptide analog
VK2735
An experimental weight-loss drug being developed as both an injection and a tablet.
Controlled human studyOther human evidence
Investigational — Phase 2 results; Phase 3 initiatedReviewed July 31, 2026
Peptide analog
Zenagamtide
An experimental weight-loss drug, previously called amycretin. Injection and tablet versions are being studied separately.
Controlled human studyOther human evidence